Independent pharmacists are dealing with the same financial pressures as the larger companies and lack control over revenue from their main product, prescription drugs.
Eight other lawsuits winding their way through the courts don't involve providers, so even if they hit a roadblock, it likely won't be for the same reason.
Just 2,000 patients have been treated so far with Leqembi, Biogen said Tuesday, a warning that the Alzheimer's drug developed with Eisai Co. may miss its target of 10,000 recipients by the end of March.